DPY30 was identified as a promoter of cancer cell proliferation and tumor survival. Targeting this protein may enhance the ...
Researchers at The University of Texas MD Anderson Cancer Center have identified an epigenetic target for replication stress, ...
Strong participation in recent $33 million common stock offering highlights investor confidence in late-stage clinical ...
Acute myeloid leukemia (AML) remains one of the most difficult blood cancers to treat. Although drug combinations are often ...
Cancer treatment has long been haunted by the same problem: how do you strike dangerous cells without hitting healthy ones ...
Potential breakthrough therapeutic targets $50B+ global immunotherapy market1 CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a ...
Strong participation in recent $33 million common stock offering highlights investor confidence in late-stage clinical momentum and commercial potential Statistical assessments point to high probabili ...
Planned interim analysis from DENALI Part 2a showed a clearly differentiated response rate at 400mg QD 5:2 over 300mg QD 5:2 and comparable ...
It's getting harder to just stumble upon games these days. There's ample trailers, previews and gameplay coverage right at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results